All In Biotech

Drug Trial Radar · NCT06534983

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Dec 9, 2024

Primary completion

Nov 10, 2027

Study completion Nov 10, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The original purpose of this study was to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study participants will be enrolled in a safety run-in phase to receive autogene cevumeran + nivolumab. This phase will be conducted to monitor and ensure the safety of study participants. After all participants in the safety run-in have been enrolled to receive autogene cevumeran + nivolumab, further participants will be randomized in either autogene cevumeran + nivolumab or the nivolumab monotherapy arm. Following the Sponsor's decision to phase out the study, as of Protocol Version 5, the primary purpose of the study is to ensure treatment continuity and safety for the participants who continue to participate in the study and receive study treatment.

Conditions

  • Muscle-invasive Urothelial Carcinoma

Interventions

  • Autogene CevumeranDrug

    Autogene cevumeran will be administered as an IV infusion per the schedule specified in the arm.

  • NivolumabDrug

    Nivolumab will be administered as an IV infusion per the schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 15 months

Locations

38 sites in 15 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey

  • MSK Monmouth

    Middletown, New Jersey

  • MSK Bergen

    Montvale, New Jersey

  • MSK Commack

    Commack, New York

  • MSK Westchester

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • MSK Nassau

    Uniondale, New York

  • Hospital Italiano

    Ciudad Autonoma Buenos Aires, Argentina

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • McGill University Health Center

    Montreal, Quebec, Canada

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Herlev Hospital

    Herlev, Denmark

  • Vivantes Klinikum Am Urban

    Berlin, Germany

  • Uniklinikum Heidelberg

    Heidelberg, Germany

  • Marien Hospital Herne

    Herne, Germany

  • Klinikum Stuttgart - Katharinenhospital

    Stuttgart, Germany

  • Theageneio Hospital

    Thessaloniki, Greece

  • A.O. Universitaria Ospedale Consorziale Policlinico Di Bari

    Bari, Apulia, Italy

  • IFO - Istituto Regina Elena

    Rome, Lazio, Italy

  • A.O. Universitaria S. Luigi Gonzaga

    Orbassano, Piedmont, Italy

  • A.O.U di Verona Policlinico G.B. Rossi

    Verona, Veneto, Italy

  • Akershus universitetssykehus

    Lørenskog, Norway

  • Centrum Onkologii im. Prof. Franciszka ?ukaszczyka

    Bydgoszcz, Poland

  • AIDPORT Sp. z o. o.

    Skórzewo, Poland

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Clinico Universitario Lozano Blesa

    Zaragoza, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona

    Sant Andreu de la Barca, Barcelona, Spain

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Chang Gung Medical Foundation - Kaohsiung

    Kaohisung, Taiwan

  • Barts & London School of Med;Medical Oncology

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.